Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis

被引：276

作者：

Cao, Fangfang ^{[1
,2
,3
,4
,5
,6
]}

Jin, Lulu ^{[1
]}

Gao, Yong ^{[1
]}

Ding, Yuan ^{[7
]}

Wen, Hongyang ^{[1
,7
]}

Qian, Zhefeng ^{[1
,7
]}

Zhang, Chenyin ^{[1
]}

Hong, Liangjie ^{[1
]}

Yang, Huang ^{[1
]}

Zhang, Jiaojiao ^{[1
]}

Tong, Zongrui ^{[1
,7
]}

Wang, Weilin ^{[7
]}

Chen, Xiaoyuan ^{[2
,3
,4
,5
,6
,8
,9
]}

Mao, Zhengwei ^{[1
,7
]}

机构：

[1] Zhejiang Univ, Dept Polymer Sci & Engn, MOE Key Lab Macromol Synth & Functionalizat, Hangzhou, Peoples R China

[2] Natl Univ Singapore, Coll Design & Engn, Yong Loo Lin Sch Med, Dept Diagnost Radiol, Singapore, Singapore

[3] Natl Univ Singapore, Coll Design & Engn, Yong Loo Lin Sch Med, Dept Surg, Singapore, Singapore

[4] Natl Univ Singapore, Coll Design & Engn, Yong Loo Lin Sch Med, Dept Chem & Biomol Engn, Singapore, Singapore

[5] Natl Univ Singapore, Coll Design & Engn, Yong Loo Lin Sch Med, Dept Biomed Engn, Singapore, Singapore

[6] Natl Univ Singapore, NUS Ctr Nanomed, Yong Loo Lin Sch Med, Nanomed Translat Res Program, Singapore, Singapore

[7] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China

[8] Natl Univ Singapore, Clin Imaging Res Ctr, Ctr Translat Med, Yong Loo Lin Sch Med, Singapore, Singapore

[9] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore

来源：

NATURE NANOTECHNOLOGY | 2023年 / 18卷 / 06期

基金：

中国国家自然科学基金;

关键词：

SUPEROXIDE-DISMUTASE; LACTOCOCCUS-LACTIS; OXYGEN REDUCTION; CROHNS-DISEASE; DELIVERY; COLITIS; ENCAPSULATION; BACTERIA; STRESS; MODELS;

D O I：

10.1038/s41565-023-01346-x

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

Approaches to treat inflammatory bowel disease with probiotics or artificial enzymes have advantages and limitations. Here we combine the advantages to overcome the individual limitations by modifying probiotics with artificial enzymes and demonstrate application in treating inflammatory bowel disease. Inflammatory bowel disease can be caused by the dysfunction of the intestinal mucosal barrier and dysregulation of gut microbiota. Traditional treatments use drugs to manage inflammation with possible probiotic therapy as an adjuvant. However, current standard practices often suffer from metabolic instability, limited targeting and result in unsatisfactory therapeutic outcomes. Here we report on artificial-enzyme-modified Bifidobacterium longum probiotics for reshaping a healthy immune system in inflammatory bowel disease. Probiotics can promote the targeting and retention of the biocompatible artificial enzymes to persistently scavenge elevated reactive oxygen species and alleviate inflammatory factors. The reduced inflammation caused by artificial enzymes improves bacterial viability to rapidly reshape the intestinal barrier functions and restore the gut microbiota. The therapeutic effects are demonstrated in murine and canine models and show superior outcomes to traditional clinical drugs.

引用

页码：617 / +

页数：19

共 63 条

[61] An Orally Administered CeO2@Montmorillonite Nanozyme Targets Inflammation for Inflammatory Bowel Disease Therapy [J].